Loading…
No business profile yet.
Size HanchorBio (7827.TW) is a Taiwan Health Care company (Biotechnology) with a market value of $462M, the 454th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$119.50 on 18 Nov 2026.
Growth The operating margin is -4,672.8% (peer median -6.9%).
Valuation It trades at 2.3× forward earnings against a peer median of 33.9× (cheapest of 6).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$27.7M | NT$312M | NT$0 | NT$0 | NT$3.36M |
| Revenue growth | — | — | — | -100% | — |
| Gross profit | -NT$39.5M | NT$274M | -NT$37.4M | -NT$33.9M | -NT$24.8M |
| EBITDA | -NT$1.25B | -NT$330M | -NT$915M | -NT$504M | -NT$485M |
| Net income | -NT$1.01B | -NT$277M | -NT$1.35B | -NT$591M | -NT$446M |
| Free cash flow | -NT$1.04B | -NT$336M | -NT$626M | -NT$462M | -NT$405M |
| Capital expenditure | NT$41.8M | NT$18.7M | NT$19.0M | NT$23.2M | NT$70.8M |
| Total debt | NT$238M | NT$101M | NT$46.3M | NT$61.0M | NT$45.2M |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7827.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -27.1% | -7.3% | 3rd lowest of 21 |
| Distance from 52-week high | -36.1% | -41.1% | 10th highest of 21 |
| Operating margin | -4,672.8% | -6.9% | 2nd lowest of 15 |
| Forward P/E | 2.3× | 33.9× | cheapest of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| HanchorBio 7827.TW | Taiwan | $462M | n/a | n/a | -4,673% | 2.3× | n/a | n/a |
| DiaMedica Therapeutics DMAC | United States | $463M | +50% | n/a | n/a | n/a | n/a | n/a |
| Kamada KMDA | United States | $465M | +3% | +5% | 15% | 17.9× | 5.0% | +6.5% |
| Shattuck Labs STTK | United States | $455M | -28% | -100% | n/a | n/a | n/a | n/a |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $470M | n/a | n/a | n/a | n/a | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $454M | -2% | -6% | -1% | n/a | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $471M | +37% | +71% | 5% | 16.9× | 58.8% | +204.7% |
| Qurient 115180.KS | South Korea | $452M | -56% | -14% | -512% | n/a | n/a | n/a |
| Neurogene NGNE | United States | $479M | -14% | -100% | n/a | n/a | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +9% | n/a | n/a | n/a | n/a | n/a |
| TaiMed Biologics 4147.TWO | Taiwan | $480M | +19% | +7% | -31% | n/a | n/a | n/a |
| EirGenix 6589.TW | Taiwan | $444M | +15% | +58% | -51% | n/a | n/a | n/a |
| Arvinas ARVN | United States | $443M | -26% | -12% | -10% | n/a | n/a | n/a |
| Crescent Biopharma CBIO | United States | $482M | -34% | n/a | -1,217% | n/a | n/a | n/a |
| IRulya Therapeutics IRLA | United States | $440M | +88% | n/a | n/a | n/a | n/a | n/a |
| Berry Genomics 000710.SZ | China | $439M | -17% | -2% | -24% | n/a | n/a | n/a |
| CHO Pharma 6586.TWO | Taiwan | $488M | +24% | -47% | -17,694% | n/a | n/a | n/a |
| Qingdao Vland Biotech 603739.SS | China | $437M | -24% | +5% | 7% | 33.9× | 7.7% | +7.3% |
| Liaoning Dingjide Petrochemical 603255.SS | China | $490M | -24% | +70% | 5% | 37.5× | n/a | n/a |
| Scinopharm Taiwan 1789.TW | Taiwan | $435M | -2% | -5% | -4% | 39.4× | 2.1% | +0.5% |
| Sinotherapeutics 688247.SS | China | $494M | -19% | -17% | 0% | n/a | 29.4% | +7.0% |